Prognostic assessment of mortality and hospitalizations of outpatients with advanced chronic obstructive pulmonary disease. Usefulness of the CODEX index

Navarro, Adria E.; Costa, R.; Rodríguez-Carballeira, Mónica; Yun, Sergi; Lapuente, A.; Barrera, A.; Acosta, E.; Viñas, Carles; Heredia, J.L.; Almagro, Pedro

doi:10.1016/j.rceng.2015.07.002

Cited by 8 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CODEX index was originally developed in a multicenter cohort of patients hospitalized for COPD exacerbation, and externally validated in the original publication in three other similar cohorts (19). Later, it was revalidated in two cohorts of ambulatory patients with good discrimination (AUC: 0.80) (20,21). This is in accordance with the data of the present study that show a higher predictive capacity in outpatients, retaining similar values of AUC to those observed in the original study for hospitalized patients.…”

Section: Discussionsupporting

confidence: 85%

“…The CODEX index was developed and validated in patients hospitalized for an acute exacerbation of COPD with the objective of evaluating the prognosis in the short-(3-months) and medium-term (1-year) for mortality, hospital readmission or their combination (19). Later, it was revalidated in a small cohort of outpatients with severe COPD for mortality and exacerbations, and more recently exclusively for mortality in another retrospective study performed in a cohort of ambulatory patients (20,21). Finally, CODEX index was compared with other index for the combination of 90-day mortality and readmissions after a hospitalization for COPD exacerbation (22).…”

Section: Individual Data On 2755 Patients Included In the Copd Cohormentioning

confidence: 99%

“…Charlson index and follow-up for mortality (20,23). All the original cohort studies were approved by the respective ethics committees and all patients gave their informed consent.…”

Section: Esmi and Egarpoc-2 Contain All The Variables Included In 3cimentioning

confidence: 99%

See 2 more Smart Citations

External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study

Almagro

Martínez‐Camblor²,

Miravitlles

et al. 2019

COPD: Journal of Chronic Obstructive Pulmonary Disease

View full text Add to dashboard Cite

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document. When citing, please reference the published version. Take down policy While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Individual Data On 2755 Patients Included In the Copd Cohormentioning

confidence: 99%

See 1 more Smart Citation

External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study

Almagro

Martínez‐Camblor²,

Miravitlles

et al. 2019

COPD: Journal of Chronic Obstructive Pulmonary Disease

View full text Add to dashboard Cite

show abstract

“…Many aspects had been focused in several studies which used a single physiological measure of lung function (i.e. FEV 1 ) [21,22], rather than complex clinical assessments [8,12,[23][24][25][26][27], or multidimensional scores [6,7,9,13,14,19].…”

Section: Discussionmentioning

confidence: 99%

“…Chronic Obstructive Pulmonary Disease (COPD) is a progressive condition which is characterized by a dramatic socio-economic impact [3,4]. The role of clinical signs, lung function, imaging, biological pictures, and multiple scores (BODE index and other composite indices, such as, BODEx; BODEm; BODEi) was extensively investigated in order to asses the mortality risk in COPD, but with variable results due to their different specificity and sensitivity [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

The BODECOST Index (BCI): a composite index for assessing the impact of COPD in real life

Negro

Celli

2016

Multidis Res Med

View full text Add to dashboard Cite

Background: Chronic Obstructive Pulmonary Disease (COPD) is a progressive condition which is characterized by a dramatic socio-economic impact. Several indices were extensively investigated in order to asses the mortality risk in COPD, but the utilization of health care resources was never included in calculations. The aim of this study was to assess the predictive value of annual cost of care on COPD mortality at three years, and to develop a comprehensive index for easy calculation of mortality risk in real life. Methods: COPD patients were anonymously and automatically selected from the local institutional Data Base. Selection criteria were: COPD diagnosis; both genders; age ≥ 40 years; availability of at least one complete clinical record/year, including history; clinical signs; complete lung function, therapeutic strategy, health BODE index; Charlson Comorbidity Index, and outcomes, collected at the first visit, and over the following 3-years. At the first visit, the health annual cost of care was calculated in each patient for the previous 12 months, and the survival rate was also measured over the following 3 years. The hospitalization and the exacerbation rate were implemented to the BODE index and the novel index thus obtained was called BODECOST index (BCI), ranging from 0 to 10 points. The mean cost for each BCI step was calculated and then compared to the corresponding patients’ survival duration. Parametrical, non parametrical tests, and linear regression were used; p < 0.05 was accepted as the lower limit of significance. Results: At the first visit, the selected 275 patients were well matched for all variables by gender. The overall mortality over the 3 year survey was 40.4 % (n = 111/275). When compared to that of BODE index (r = 0.22), the total annual cost of care and the number of exacerbations showed the highest regression value vs the survival time (r = 0.58 and r = 0.44, respectively). BCI score proved strictly proportional to both the cost of care and the survival time in our sample of COPD patients. Discussion: BCI takes origin from the implementation of the BODE index with the two main components of the annual cost of care, such as the number of hospitalizations and of exacerbations occurring yearly in COPD patients, and their corresponding economic impact. In other words, higher the BCI score, shorter the survival and higher the cost, these trends being strictly linked. Conclusions: BCI is a novel composite index which helps in predicting the impact of COPD at 3 years in real life, both in terms of patients’ survival and of COPD economic burden.

show abstract

Consenso para el manejo de pacientes con EPOC según el índice CODEX

Boixeda

Díez-Manglano

Gomez-Antunez

et al. 2019

Revista Clínica Española

View full text Add to dashboard Cite

Prognostic assessment of mortality and hospitalizations of outpatients with advanced chronic obstructive pulmonary disease. Usefulness of the CODEX index

Cited by 8 publications

References 39 publications

External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study

External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study

The BODECOST Index (BCI): a composite index for assessing the impact of COPD in real life

Consenso para el manejo de pacientes con EPOC según el índice CODEX

Contact Info

Product

Resources

About